ArticleImmunotherapy2023

An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.

Gordon Taylor Moffat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.